PAK2 (Y443N)
Sign in to save this workspacePAK2 · Variant type: point · HGVS: p.Y443N
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Neratinib | 75.5% | 24.5% | 93.18 |
| 2 | Ripretinib | 14.5% | 85.5% | 92.95 |
| 3 | Defactinib | 9.4% | 90.6% | 92.68 |
| 4 | Infigratinib | 8.0% | 92.0% | 98.24 |
| 5 | Pexidartinib | 7.7% | 92.3% | 99.49 |
| 6 | Pralsetinib | 7.4% | 92.6% | 93.43 |
| 7 | Pirtobrutinib | 6.2% | 93.8% | 99.49 |
| 8 | Sorafenib | 6.1% | 93.9% | 96.72 |
| 9 | Entrectinib | 5.9% | 94.1% | 93.69 |
| 10 | Tenalisib | 5.7% | 94.3% | 97.98 |
| 11 | Gedatolisib | 5.5% | 94.5% | 99.75 |
| 12 | Fedratinib | 5.1% | 94.9% | 96.21 |
| 13 | Gilteritinib | 5.1% | 94.9% | 88.97 |
| 14 | Palbociclib | 4.9% | 95.1% | 98.75 |
| 15 | Pacritinib | 4.9% | 95.1% | 88.64 |
| 16 | Tucatinib | 4.9% | 95.1% | 99.75 |
| 17 | Sunitinib | 4.6% | 95.4% | 91.73 |
| 18 | Tepotinib | 4.2% | 95.8% | 99.75 |
| 19 | Repotrectinib | 3.3% | 96.7% | 84.21 |
| 20 | Alpelisib | 3.3% | 96.7% | 97.22 |
| 21 | Deucravacitinib | 2.7% | 97.3% | 98.99 |
| 22 | Idelalisib | 2.6% | 97.4% | 100.00 |
| 23 | Canertinib | 2.5% | 97.5% | 96.49 |
| 24 | Vandetanib | 2.4% | 97.6% | 95.74 |
| 25 | Paxalisib | 2.3% | 97.7% | 99.75 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Neratinib | 75.5% | 87.7% | -12.2% |
| Ripretinib | 14.5% | — | — |
| Defactinib | 9.4% | 29.9% | -20.5% |
| Infigratinib | 8.0% | — | — |
| Pexidartinib | 7.7% | — | — |
| Pralsetinib | 7.4% | 15.6% | -8.2% |
| Pirtobrutinib | 6.2% | — | — |
| Sorafenib | 6.1% | — | — |
| Entrectinib | 5.9% | — | — |
| Tenalisib | 5.7% | 11.7% | -6.0% |
| Gedatolisib | 5.5% | — | — |
| Fedratinib | 5.1% | — | — |
| Gilteritinib | 5.1% | — | — |
| Palbociclib | 4.9% | — | — |
| Pacritinib | 4.9% | 21.4% | -16.5% |
| Tucatinib | 4.9% | — | — |
| Sunitinib | 4.6% | — | — |
| Tepotinib | 4.2% | — | — |
| Repotrectinib | 3.3% | — | — |
| Alpelisib | 3.3% | — | — |
| Deucravacitinib | 2.7% | — | — |
| Idelalisib | 2.6% | — | — |
| Canertinib | 2.5% | — | — |
| Vandetanib | 2.4% | — | — |
| Paxalisib | 2.3% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| Colon/Colorectal Cancer | Large Intestine | ref |
| carcinoma_ovary | Ovary | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.3ms